Virginia Retirement Systems ET AL purchased a new position in Clorox Co. (NYSE:CLX) during the second quarter, Holdings Channel reports. The fund purchased 39,800 shares of the company’s stock, valued at approximately $5,508,000.

Several other institutional investors have also recently made changes to their positions in CLX. Vanguard Group Inc. boosted its position in shares of Clorox by 1.4% in the second quarter. Vanguard Group Inc. now owns 13,389,707 shares of the company’s stock worth $1,853,001,000 after buying an additional 188,564 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in shares of Clorox by 7.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 4,504,422 shares of the company’s stock worth $567,827,000 after buying an additional 313,224 shares in the last quarter. BlackRock Group LTD boosted its position in shares of Clorox by 18.2% in the first quarter. BlackRock Group LTD now owns 1,592,689 shares of the company’s stock worth $200,775,000 after buying an additional 245,650 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Clorox by 2.7% in the first quarter. Geode Capital Management LLC now owns 1,182,810 shares of the company’s stock worth $148,838,000 after buying an additional 30,881 shares in the last quarter. Finally, Swiss National Bank boosted its position in shares of Clorox by 3.2% in the second quarter. Swiss National Bank now owns 794,392 shares of the company’s stock worth $109,936,000 after buying an additional 24,500 shares in the last quarter. 70.17% of the stock is currently owned by institutional investors.

Clorox Co. (NYSE:CLX) opened at 122.67 on Tuesday. The stock’s 50 day moving average is $129.73 and its 200 day moving average is $130.12. Clorox Co. has a 1-year low of $112.75 and a 1-year high of $140.47. The firm has a market capitalization of $15.88 billion, a price-to-earnings ratio of 24.93 and a beta of 0.33.

Clorox (NYSE:CLX) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported $1.26 EPS for the quarter, missing the Zacks’ consensus estimate of $1.28 by $0.02. Clorox had a net margin of 11.25% and a return on equity of 296.91%. The firm earned $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. During the same period in the prior year, the company posted $1.44 earnings per share. The company’s revenue for the quarter was up 2.8% compared to the same quarter last year. Analysts predict that Clorox Co. will post $5.49 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 14th. Stockholders of record on Wednesday, October 26th will be paid a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a dividend yield of 2.61%. The ex-dividend date is Monday, October 24th. Clorox’s dividend payout ratio is currently 64.91%.

A number of equities analysts have recently weighed in on CLX shares. Jefferies Group reissued a “hold” rating on shares of Clorox in a research report on Wednesday, August 3rd. B. Riley reissued a “neutral” rating and set a $109.00 price target on shares of Clorox in a research report on Tuesday, August 9th. Atlantic Securities assumed coverage on shares of Clorox in a report on Tuesday, June 14th. They set a “neutral” rating and a $138.00 price objective on the stock. Deutsche Bank AG restated a “hold” rating and set a $134.00 price objective (up from $130.00) on shares of Clorox in a report on Sunday, July 24th. Finally, Zacks Investment Research lowered shares of Clorox from a “hold” rating to a “sell” rating in a report on Tuesday, July 5th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the stock. Clorox currently has an average rating of “Hold” and an average target price of $128.90.

In related news, EVP Laura Stein sold 38,882 shares of the stock in a transaction on Friday, September 2nd. The shares were sold at an average price of $131.69, for a total transaction of $5,120,370.58. Following the transaction, the executive vice president now directly owns 48,501 shares of the company’s stock, valued at $6,387,096.69. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Jon M. Balousek sold 5,136 shares of the stock in a transaction on Monday, August 29th. The stock was sold at an average price of $131.14, for a total transaction of $673,535.04. Following the transaction, the senior vice president now directly owns 15,384 shares in the company, valued at $2,017,457.76. The disclosure for this sale can be found here. 2.09% of the stock is currently owned by insiders.

About Clorox

The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.

5 Day Chart for NYSE:CLX

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co. (NYSE:CLX).

Receive News & Ratings for Clorox Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox Co. and related companies with MarketBeat.com's FREE daily email newsletter.